Urocortin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2

被引：44

作者：

Wang, Juejin ^{[1
]}

Xu, Youhua ^{[1
]}

Xu, Yinyan

Zhu, Huayuan ^{[2
]}

Zhang, Rongjian ^{[1
]}

Zhang, Guoxin ^{[3
]}

Li, Shengnan ^{[1
]}

机构：

[1] Nanjing Med Univ, Dept Pharmacol, Nanning, Peoples R China

[2] Nanjing Med Univ, Affiliated Hosp 1, Dept Internal Med, Nanjing, Peoples R China

[3] Nanjing Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Nanjing, Peoples R China

来源：

CANCER INVESTIGATION | 2008年 / 26卷 / 04期

基金：

中国国家自然科学基金;

关键词：

urocortin; corticotrophin-releasing factor receptor (CRFR); tumor angiogenesis; hepatocellular carcinoma (HCC); vascular endothelial growth factor (VEGF);

D O I：

10.1080/07357900701788106

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Urocortin (UCN) functions via corticotrophin-releasing factor receptors (CRFRs), CRFR1 2. CRFR2 is reported to be a tonic suppressor of vascularization, implying its role in tumor angiogenesis. Here, it was found that UCN inhibited the growth of hepatocellular carcinoma (HCC) and reduced tumor microvessel density in nude mice. Hepatoma cells didn't express CRFRs whereas vessels expressed CRFRs, mainly CRFR2. In vitro three-dimensional culture assay showed UCN inhibited angiogenesis, this effect was abolished by CRFR2 antagonist, anti-sauvagine-30, demonstrating involvement of CRFR2. Furthermore, UCN inhibited the proliferation and promoted the apoptosis of endothelial cells and down-regulated VEGF expression in vivo via CRFR2.

引用

页码：359 / 368

页数：10

共 25 条

[1] Corticotropin-releasing hormone stimulates angiogenesis and epithelial tumor growth in the skin [J].

Arbiser, JL ;

Karalis, K ;

Viswanathan, A ;

Koike, C ;

Anand-Apte, B ;

Flynn, E ;

Zetter, B ;

Majzoub, JA .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 113 (05) :838-842

[2] Expression of urocortin mRNA and peptide in the human prostate and in prostatic adenocarcinoma [J].

Arcuri, F ;

Cintorino, M ;

Florio, P ;

Floccari, F ;

Pergola, L ;

Romagnoli, R ;

Petraglia, F ;

Tosi, P ;

del Vecchio, MT .

PROSTATE, 2002, 52 (03) :167-172

[3] Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization [J].

Bale, TL ;

Giordano, FJ ;

Hickey, RP ;

Huang, Y ;

Nath, AK ;

Peterson, KL ;

Vale, WW ;

Lee, KF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (11) :7734-7739

[4] Tumorigenesis and the angiogenic switch [J].

Bergers, G ;

Benjamin, LE .

NATURE REVIEWS CANCER, 2003, 3 (06) :401-410

[5] Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor [J].

Cao, J ;

Papadopoulou, N ;

Kempuraj, D ;

Boucher, WS ;

Sugimoto, K ;

Cetrulo, CL ;

Theoharides, TC .

JOURNAL OF IMMUNOLOGY, 2005, 174 (12) :7665-7675

[6]

Carlson KW, 2001, ANTICANCER RES, V21, P1173

[7] FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition [J].

Cross, MJ ;

Claesson-Welsh, L .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (04) :201-207

[8] Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: Ancient CRF paralogs [J].

Fekete, Eva M. ;

Zorrilla, Eric P. .

FRONTIERS IN NEUROENDOCRINOLOGY, 2007, 28 (01) :1-27

[9] Urocortin expression is downregulated in human endometrial carcinoma [J].

Florio, Pasquale ;

De Falco, Giulia ;

Leucci, Eleonora ;

Torricelli, Michela ;

Torres, Paulo B. ;

Toti, Paolo ;

Dell'Anna, Arianna ;

Tiso, Ennio ;

Santopietro, Rosa ;

Leoncini, Lorenzo ;

Petraglia, Felice .

JOURNAL OF ENDOCRINOLOGY, 2006, 190 (01) :99-105

[10]

FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182

← 1 2 3 →